ASMB
vs
S&P 500
ASMB
S&P 500
Over the past 12 months, ASMB has significantly outperformed S&P 500, delivering a return of +58% compared to S&P 500's +19% growth.
Stocks Performance
ASMB vs S&P 500
Performance Gap
ASMB vs S&P 500
Performance By Year
ASMB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Assembly Biosciences Inc
Glance View
Assembly Biosciences is a biotechnology company that develops medicines for viral diseases, especially hepatitis B and herpesvirus infections such as herpes simplex. It does not sell consumer products; its main job is to discover and test antiviral drug candidates in the lab and in clinical trials, then move the most promising ones forward toward approval. The company’s customers are not patients directly. Its main business partners are larger pharmaceutical companies, research collaborators, and, if any drug reaches the market, healthcare providers and patients who would use the medicine. Assembly Biosciences makes money mainly through research collaborations, licensing deals, and funding tied to drug development milestones, with future revenue potential from any approved therapies it may help bring to market. What makes the business different is that it sits very early in the drug value chain. Instead of selling a broad range of medicines, it focuses on a small number of hard-to-treat viral targets where new treatments can be valuable. That gives the company a high-risk, high-reward profile typical of biotech: most value depends on whether its drug candidates prove safe, effective, and commercially useful.
